Ernexa Therapeutics Inc. Deferred State and Local Income Tax Expense (Benefit)
Ernexa Therapeutics Inc. (ERNA) reported Deferred State and Local Income Tax Expense (Benefit) of -$67.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-03-13
- Ernexa Therapeutics Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was -$67.00K, a 348.15% decline from fiscal 2024.
- Ernexa Therapeutics Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $27.00K.
- Ernexa Therapeutics Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$4.00K.
- Ernexa Therapeutics Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$1.60M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$67.00K 10-K · filed 2026-03-13 | |
| 2024-12-31 | $27.00K 10-K · filed 2026-03-13 | |
| 2023-12-31 | -$4.00K 10-K · filed 2025-03-12 | $8.00K 10-K · filed 2024-03-14 |
| 2022-12-31 | -$1.60M 10-K · filed 2024-03-14 | |
| 2021-12-31 | -$1.41M 10-K · filed 2023-03-20 | -$1.43M 10-K · filed 2022-04-15 |
| 2020-12-31 | -$322.00K 10-K/A · filed 2022-07-01 | -$12.00K 10-K · filed 2021-03-11 |
| 2019-12-31 | $2.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $6.00K 10-K · filed 2020-03-19 | -$6.00K 10-K · filed 2019-03-22 |
| 2017-12-31 | -$24.00K 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$4.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | -$4.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | -$4.00K 10-K · filed 2016-03-15 | |
| 2013-12-31 | -$3.00K 10-K · filed 2015-03-27 | |
| 2012-12-31 | $77.00K 10-K · filed 2014-03-31 | -$77.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |